ULBP-4/RAET1E Antibody (709116) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

ULBP-4 (cytomegalovirus glycoprotein UL16 binding protein 4), also called RAET1E (retinoic acid early transcript 1E), Letal (lymphocyte effector cell toxicity activating ligand) and NKG2DL4 (NKG2D ligand 4), is a 40-50 kDa member of the ULBP/RAET1 family of cell surface proteins that function as ligands for NKG2D (1‑6). While most family members are GPI-anchored, only ULBP-4/RAET1E and ULBP-5/RAET1G express a transmembrane form (1, 4, 6, 7). Human ULBP-4 mRNA encodes 263 amino acids (aa) including a 30 aa signal sequence, a 195 aa extracellular domain (ECD), a 23 aa transmembrane domain, and a 15 aa cytoplasmic sequence. A soluble 35 kDa form diverges at aa 208 and is thought to antagonize the transmembrane form (5). Other potential splice variants of 220, 227 and 280 aa are transmembrane proteins (8). Within the ECD, ULBP-4 shares 34-41% aa sequence identity with family members (1, 7). Rodent NKG2D ligands Rae-1 alpha -epsilon are, like human ULBP and MIB proteins, distantly related to MHC class I proteins, but none of the families share significant sequence identity (2, 4). Low expression of ULBP‑4 mRNA is found in normal tissues, with high expression variably reported in the small intestine (3) and skin (4). Expression is stimulated by TNF-alpha and down‑regulated by retinoic acid (3). ULBP-4 is abnormally expressed on most colon cancer and some other tumor cell lines and virus-infected peripheral blood cells (3, 6). ULBP-4 binds and costimulates NKG2D-expressing effector cells including NK cells, NKT cells, gamma δ T cells, and CD8⁺ alpha beta T cells, activating cytolytic activity and/or cytokine production (3, 4, 7). In some gamma δ T cells, direct ULBP-4 binding to both TCR gamma δ and NKG2D has been demonstrated (6). ULBP-4 is also thought to function as a minor histocompatibility antigen in humans (1).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: Flow Cytometry, IHC-P.

Showing Publications 1 - 5 of 5.

Publications using MAB6285	Applications	Species
M Lazarova, Y Kim, A Steinle The NKG2D ligand ULBP4 is not expressed by human monocytes PLoS ONE, 2021-02-08;16(2):e0246726. 2021-02-08 [PMID: 33556116] (Flow Cytometry, Human)	Flow Cytometry	Human
R Okita, A Maeda, K Shimizu, Y Nojima, S Saisho, M Nakata Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer Oncotarget, 2019-11-26;10(63):6805-6815. 2019-11-26 [PMID: 31827723] (IHC-P, Human)	IHC-P	Human
B Chen, JB Lee, H Kang, MD Minden, L Zhang Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy J. Exp. Clin. Cancer Res., 2018-04-24;37(1):88. 2018-04-24 [PMID: 29690909] (Flow Cytometry, Human)	Flow Cytometry	Human
C Breunig, J Pahl, M Küblbeck, M Miller, D Antonelli, N Erdem, C Wirth, R Will, A Bott, A Cerwenka, S Wiemann MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells Cell Death Dis, 2017-08-03;8(8):e2973. 2017-08-03 [PMID: 28771222] (Flow Cytometry, Human)	Flow Cytometry	Human
NA Zumwalde, A Sharma, X Xu, S Ma, CL Schneider, JC Romero-Mas, AW Hudson, A Gendron-Fi, SC Kenney, JE Gumperz Adoptively transferred V?9V?2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model JCI Insight, 2017-07-06;2(13):. 2017-07-06 [PMID: 28679955] (Flow Cytometry, Human)	Flow Cytometry	Human

Array MAB6285

• ULBP-4/RAET1E Antibodies
• ULBP-4/RAET1E Lysate
• ULBP-4/RAET1E Protein
• ULBP-4/RAET1E Proteins and Enzyme